Seeking Alpha
Biotech, healthcare, tech
Profile| Send Message|
( followers)  

We're going to have to wait to find out if the whole Schering-Plough (SGP)-buys-Merck (NYSE:MRK) charade is really going to allow revenue from J&J's (NYSE:JNJ) Remicade to stay with the merged company. That merged company is known as "Merck", of course, and is run by Merck people from Merck's headquarters, so it's going to be interesting to see how that dispute goes.

Although the first arguments have been made before an arbitration board, the decision doesn't look to be made until sometime next year. It sounds as if Merck is already trying to lower expectations, though..

Source: Merck vs. J&J: Wait for It